| BIT's 16th Annual Congress of International Drug Discovery Science and Technology-2018 | ||||
| Theme: Rethinking the Next Big Things in Pharma Innovations | ||||
| Time: August 16-19, 2018 Place: Boston Marriott Cambridge, USA |
||||
| Scientific Program | ||||
| Stream 1 | Stream 2 | Stream 3 | Stream 4 | Stream 5 |
| Stream 3: Industrial Art Gallery -Arts in Billion Dollar Molecules and Next Generation Therapy |
Substream 3-1: Improved Linear Drug Discovery on Selected Current Drug Targets Substream 3-6: Clinical Trial Gateway and Translational Convergence |
| Substream 3-4: Novel Biotherapeutic Discovery |
|||
|
Session 3401: Novel Biotherapeutic Discovery Day 2: Morning, Friday, August 17, 2018 Place: Concept Room, 2nd Floor 08:30-12:10 |
|||
| Chair: Dr. Wei-Chiang Shen, John A. Biles Professor, Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, USA | |||
|
Co-Chair: Dr. Marcie Glicksman, Chief Scientific Officer, Orig3n, Inc., USA |
|||
| Time | FaceOn | Speeches and Speakers | |
| 08:30-08:35 | Chair's Introduction | ||
| 08:35-09:00 |  |
Title: Impact of Antibody Subclass Differences on Functional Activity of Monoclonal Antibodies Dr. John Delaney, Executive Director, Discovery Research; Site Head, Amgen British Columbia, Amgen, Inc, USA |
|
| 09:00-09:25 |  |
Title: Glycan-mediated Site-specific Antibody Conjugation Dr. Qun Zhou, Protein Engineering, Biologics Research US, Sanofi, USA
|
|
| 09:25-09:50 |  |
Title: Antibody Avidity Modulated by Reversible Post-translational Modification: Potential On/Off Switch? Dr. Troy McSherry, Principal Research Scientist, Abbott Laboratories, USA |
|
| 09:50-10:15 |  |
Title: The Future of Medicine: Using iPSCs for Disease Modeling & Therapeutics Dr. Marcie Glicksman, Chief Scientific Officer, Orig3n, Inc., USA |
|
| 10:15-10:30 | Coffee Break | ||
| 10:30-10:55 |  |
Title: Recombinant Proinsulin-transferrin Fusion Protein as a Liver-targeted Insulin Prodrug Dr. Wei-Chiang Shen, John A. Biles Professor, University of Southern California School of Pharmacy, USA |
|
| 10:55-11:20 |  |
Title: Anti-inflammatory Effect of Baicalein on Polyinosinic⁻ Polycytidylic Acid-induced RAW 264.7 Mouse Macrophages Dr. Wansu Park, Chief Professor, Department of Pathology, College of Korean Medicine, Gachon University, South Korea |
|
| 11:20-11:45 |  |
Title: Antibody Designability for Rational Clone Selection Dr. Hiroki Shirai, Executive Fellow, Modality Research Labs, Astellas Pharma Inc., Japan |
|
| 11:45-12:10 |  |
Title: Development of Novel Mycobacterial Hsp70-containing Fusion Proteins as Vaccines and Immunotherapies for Cancer Dr. Patrick Reeves, Lead Scientist, Vaccine and Immunotherapy Center, Massachusetts General Hospital; Research Fellow, Harvard Medical School, USA |
|
|
Session 3402: Bio-Hybrids and Novel Biosimilars Day 2: Afternoon, Friday, August 17, 2018 Place: Enterprise Room, 3rd Floor 15:25-17:10 |
|||
| Chair: Mr. Todd Lester, Bioanalytical Project Manager, BioAgilytix, USA | |||
| Time | FaceOn | Speeches and Speakers | |
| 15:25-15:30 | Chair's Introduction | ||
| 15:30-15:55 |  |
Title: Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment Mr. Todd Lester, Bioanalytical Project Manager, BioAgilytix, USA |
|
| 15:55-16:20 |  |
Title: Crossing to the Other Side Dr. Albin (Jim) Nelson, Senior Principal/Owner, Schwegman Lundberg & Woessner P.A., USA
|
|
| 16:20-16:45 |  |
Title: Clinical Pharmacology Considerations of Bispecific Biologics Dr. Ping Ji, Special Assistant, Food and Drug Administration, USA |
|
| 16:45-17:10 |  |
Title: Growth Opportunities in Biosimilars Industry - Building Partnerships in Oncology Market Mr. Nitin Naik, Global Vice President, Life Sciences, Frost & Sullivan, USA |
|
© 2003-2018 All rights reserved by BITeomics Inc. |